

## Risdiplam 0.75mg/mL powder for oral solution (Evrysdi®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2401	For the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA type 1, type 2 or type 3 or with one to four SMN2 [survival of motor neuron 2] copies.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/05/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/risdiplam-evrysdi-full-smc2401/>

### Other Decision Specified

**Date of ADTC** 16/02/2022

---

## Diroximel fumarate 231mg gastro-resistant hard capsules (Vumerity®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2444	Treatment of adult patients with relapsing remitting multiple sclerosis.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/05/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/diroximel-fumarate-vumerity-abb-smc2444/>

### Other Decision Specified

**Date of ADTC** 16/02/2022

---

### Cenobamate 12.5mg, 25mg, 50mg, 100mg, 150mg, and 200mg film-coated tablets (Ontozry®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2408	<p>For the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products.</p> <p>SMC restriction: in patients with drug-resistant epilepsy as a second-line adjunctive antiseizure medicine, after the failure of the first adjunctive anti-seizure medicine.</p>	Available in line with local or regional guidance	16/03/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/cenobamate-ontozry-full-smc2408/>

#### Other Decision Specified

**Date of ADTC** 16/02/2022

---

## Cannabidiol 100mg/mL oral solution (Epidyolex®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2402	For use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/05/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/cannabidiol-epidyolex-tsc-full-smc2402/>

### Other Decision Specified

**Date of ADTC** 16/02/2022

## Pemigatinib 4.5mg, 9mg, and 13.5mg tablets (Pemazyre®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2399	For the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.	Available in line with local or regional guidance	18/05/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/pemigatinib-pemazyre-full-smc2399/>

### Other Decision Specified

**Date of ADTC** 16/02/2022

## Enzalutamide 40mg film-coated tablets (Xtandi®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2400	Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).	Available in line with local or regional guidance	18/05/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/enzalutamide-xtandi-full-smc2400/>

### Other Decision Specified

**Date of ADTC** 16/02/2022

## Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2385	In combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).	Available in line with local or regional guidance	18/05/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/nivolumab-opdivo-full-smc2385/>

### Other Decision Specified

**Date of ADTC** 16/02/2022